3.0.0 2699 2023-01-13T04:48:21Z 2023-01-13T04:48:21Z Senate S S 2006-05-02 109 ssju00 Judiciary Committee Senate Standing Referred to 2006-05-02T23:07:57Z 2006-05-02 ssju00 Judiciary Committee Senate Read twice and referred to the Committee on the Judiciary. IntroReferral 2006-05-02 Sponsor introductory remarks on measure. (CR S3900) IntroReferral B00100 9 Library of Congress 2006-05-02 Introduced in Senate IntroReferral 10000 9 Library of Congress B000953 Sen. Brownback, Sam [R-KS] SAM BROWNBACK R KS N L000304 Sen. Lieberman, Joseph I. [D-CT] JOSEPH LIEBERMAN D CT I. 2006-05-02 True Commerce AIDS (Disease) Antibiotics Communicable diseases Congress Congressional reporting requirements Drug approvals Drug industry Drugs Government Operations and Politics Government paperwork Governmental investigations Health Human immunodeficiency viruses Intellectual property Malaria Patents Tuberculosis World health Commerce 00 2006-05-02 Introduced in Senate 2006-06-13T19:32:03Z Elimination of Neglected Diseases Act of 2006 - Provides for the extension and restoration of the patent term for a certified tropical disease product: (1) that is used to treat neglected or tropical diseases such as HIV, malaria, tuberculosis, or other infectious disease that disproportionately affect poor and marginalized populations; and (2) the patent for which claims an approved new molecular entity standard review drug or the process of making such a drug or the drug's active ingredient.

Requires the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to: (1) designate as a new molecular entity standard review drug a drug that has a new molecular entity chemical type classification and standard review drug treatment potential classifications and is not a drug developed to treat serious or life-threatening diseases; and (2) maintain and annually update a classification list of serious and life-threatening diseases. Allows the Secretary, acting through the Commissioner, to remove the designation of a drug as a new molecular entity standard review drug.

Requires the Director of the United States Patent and Trademark Office (USPTO) to study the effect of patent extension and restoration on the ability of pharmaceutical companies to develop and distribute tropical disease products for poor and marginalized populations.

]]> Elimination of Neglected Diseases Act of 2006 Display Title Elimination of Neglected Diseases Act of 2006 Official Title as Introduced A bill to promote the research and development of drugs related to neglected and tropical diseases, and for other purposes. Introduced in Senate IS Short Titles as Introduced Elimination of Neglected Diseases Act of 2006 Introduced in Senate 2006-05-02T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-109s2699is/xml/BILLS-109s2699is.xml 2006-05-02 Read twice and referred to the Committee on the Judiciary. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.